Medigene with strong impulseIs medigene breaking out of trendchannel or simply overbought right now. CRS and RSI strong.
Came out of a bollinger squeeze and rising.
How can you tell if its a breakout from trend? Will it continue or fall back?
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.232 EUR
−16.18 M EUR
6.03 M EUR
6.92 M
About MEDIGENE AG
Sector
Industry
CEO
Selwyn Ho
Website
Headquarters
Martinsried
Founded
1996
ISIN
DE000A40ESG2
FIGI
BBG000DZGHK0
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MDG1 is 1.550 EUR — it has decreased by −0.12% in the past 24 hours. Watch MEDIGENE AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange MEDIGENE AG stocks are traded under the ticker MDG1.
MDG1 stock has fallen by −15.75% compared to the previous week, the month change is a −23.95% fall, over the last year MEDIGENE AG has showed a −48.91% decrease.
We've gathered analysts' opinions on MEDIGENE AG future price: according to them, MDG1 price has a max estimate of 6.00 EUR and a min estimate of 6.00 EUR. Watch MDG1 chart and read a more detailed MEDIGENE AG stock forecast: see what analysts think of MEDIGENE AG and suggest that you do with its stocks.
MDG1 reached its all-time high on Feb 21, 2018 with the price of 36.706 EUR, and its all-time low was 1.552 EUR and was reached on Nov 1, 2024. View more price dynamics on MDG1 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MDG1 stock is 4.26% volatile and has beta coefficient of 0.77. Track MEDIGENE AG stock price on the chart and check out the list of the most volatile stocks — is MEDIGENE AG there?
Today MEDIGENE AG has the market capitalization of 11.91 M, it has decreased by −11.18% over the last week.
Yes, you can track MEDIGENE AG financials in yearly and quarterly reports right on TradingView.
MEDIGENE AG is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
MDG1 earnings for the last half-year are −0.52 EUR per share, whereas the estimation was −0.56 EUR, resulting in a 7.14% surprise. The estimated earnings for the next half-year are −0.38 EUR per share. See more details about MEDIGENE AG earnings.
MEDIGENE AG revenue for the last half-year amounts to 4.48 M EUR, despite the estimated figure of 4.15 M EUR. In the next half-year revenue is expected to reach 6.52 M EUR.
MDG1 net income for the last half-year is −6.73 M EUR, while the previous report showed −9.21 M EUR of net income which accounts for 26.95% change. Track more MEDIGENE AG financial stats to get the full picture.
No, MDG1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 86.00 employees. See our rating of the largest employees — is MEDIGENE AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDIGENE AG EBITDA is −14.26 M EUR, and current EBITDA margin is −249.04%. See more stats in MEDIGENE AG financial statements.
Like other stocks, MDG1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDIGENE AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDIGENE AG technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDIGENE AG stock shows the strong sell signal. See more of MEDIGENE AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.